Loading...
XNAS
SSKN
Market cap6mUSD
Dec 05, Last price  
1.44USD
1D
-1.37%
1Q
-19.10%
Jan 2017
-93.45%
IPO
-99.94%
Name

STRATA Skin Sciences Inc

Chart & Performance

D1W1MN
XNAS:SSKN chart
P/E
P/S
0.18
EPS
Div Yield, %
Shrs. gr., 5y
64.11%
Rev. gr., 5y
1.22%
Revenues
34m
+0.61%
0000000278,461536,000915,00018,495,00031,757,00031,449,00029,855,00031,586,00023,090,00029,977,00036,161,00033,357,99933,562,000
Net income
-10m
L-6.87%
-6,726,347-10,591,477-11,937,444-17,605,031-18,452,844-19,922,515-20,384,715-22,673,000-25,948,000-16,032,000-27,909,000-3,335,000-21,514,000-4,033,000-3,790,000-4,412,000-2,706,000-5,549,000-10,830,000-10,086,000
CFO
188k
P
-5,865,133-10,141,345-11,048,937-16,204,517-17,302,714-18,820,489-17,457,861-19,223,676-19,413,000-17,709,000-6,585,000322,0004,140,0002,896,0002,229,0002,096,0001,508,000-1,108,000-519,000188,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
IPO date
Oct 28, 2005
Employees
114
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT